Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC-Guided Personalized Therapy for Peritoneal Mesothelioma
NCT07330271Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Dec 2025
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in malignant peritoneal mesothelioma (MPM) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Overall Survival at 5 years. Started Dec 2025; status: recruiting.
02
Conditions
malignant peritoneal mesothelioma (MPM)
Beyond the preview
Go deeper on NCT07330271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330271.